260 related articles for article (PubMed ID: 21599917)
1. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population.
Primatesta P; Plana E; Rothenbacher D
BMC Musculoskelet Disord; 2011 May; 12():103. PubMed ID: 21599917
[TBL] [Abstract][Full Text] [Related]
2. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
[TBL] [Abstract][Full Text] [Related]
3. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
4. Gout medication treatment patterns and adherence to standards of care from a managed care perspective.
Sarawate CA; Brewer KK; Yang W; Patel PA; Schumacher HR; Saag KG; Bakst AW
Mayo Clin Proc; 2006 Jul; 81(7):925-34. PubMed ID: 16835972
[TBL] [Abstract][Full Text] [Related]
5. Frequency and risk factors of gout flares in a large population-based cohort of incident gout.
Rothenbacher D; Primatesta P; Ferreira A; Cea-Soriano L; Rodríguez LA
Rheumatology (Oxford); 2011 May; 50(5):973-81. PubMed ID: 21228059
[TBL] [Abstract][Full Text] [Related]
6. Serum urate levels and gout flares: analysis from managed care data.
Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
8. Benefit restrictions and gout treatment.
Wang SM; Aranda GA; Gao S; Patel BV
J Manag Care Pharm; 2013; 19(9):773-82. PubMed ID: 24156646
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers.
Juge PA; Truchetet ME; Pillebout E; Ottaviani S; Vigneau C; Loustau C; Cornec D; Pascart T; Snanoudj R; Bailly F; Cornec-Le Gall E; Schaeverbeke T; Saraux A; Dieudé P; Flipo RM; Richette P; Lioté F; Bardin T; Chalès G; Ea HK
Joint Bone Spine; 2017 Oct; 84(5):595-598. PubMed ID: 27825577
[TBL] [Abstract][Full Text] [Related]
10. Management of gout in the older adult.
Fravel MA; Ernst ME
Am J Geriatr Pharmacother; 2011 Oct; 9(5):271-85. PubMed ID: 21849262
[TBL] [Abstract][Full Text] [Related]
11. Gout, flares, and allopurinol use: a population-based study.
Proudman C; Lester SE; Gonzalez-Chica DA; Gill TK; Dalbeth N; Hill CL
Arthritis Res Ther; 2019 May; 21(1):132. PubMed ID: 31151457
[TBL] [Abstract][Full Text] [Related]
12. GOSPEL 2 - Colchicine for the treatment of gout flares in France - a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age.
Pascart T; Lancrenon S; Lanz S; Delva C; Guggenbuhl P; Lambert C; Aubert JP; Saraux A; Ea HK; Lioté F
Joint Bone Spine; 2016 Dec; 83(6):687-693. PubMed ID: 26919801
[TBL] [Abstract][Full Text] [Related]
13. Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy.
Drivelegka P; Sigurdardottir V; Svärd A; Jacobsson LTH; Dehlin M
Arthritis Res Ther; 2018 Jun; 20(1):108. PubMed ID: 29855389
[TBL] [Abstract][Full Text] [Related]
14. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).
Mikuls TR; Farrar JT; Bilker WB; Fernandes S; Saag KG
Rheumatology (Oxford); 2005 Aug; 44(8):1038-42. PubMed ID: 15870145
[TBL] [Abstract][Full Text] [Related]
15. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G
Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of contraindications and prescription of pharmacologic therapies for gout.
Keenan RT; O'Brien WR; Lee KH; Crittenden DB; Fisher MC; Goldfarb DS; Krasnokutsky S; Oh C; Pillinger MH
Am J Med; 2011 Feb; 124(2):155-63. PubMed ID: 21295195
[TBL] [Abstract][Full Text] [Related]
17. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Bakris GL; Doghramji PP; Keenan RT; Silber SH
Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
[TBL] [Abstract][Full Text] [Related]
18. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.
Riedel AA; Nelson M; Joseph-Ridge N; Wallace K; MacDonald P; Becker M
J Rheumatol; 2004 Aug; 31(8):1575-81. PubMed ID: 15290738
[TBL] [Abstract][Full Text] [Related]
19. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.
Annemans L; Spaepen E; Gaskin M; Bonnemaire M; Malier V; Gilbert T; Nuki G
Ann Rheum Dis; 2008 Jul; 67(7):960-6. PubMed ID: 17981913
[TBL] [Abstract][Full Text] [Related]
20. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
Singh JA; Yang S; Saag KG
J Rheumatol; 2020 Mar; 47(3):449-460. PubMed ID: 31416925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
